Curis, Inc.
CRISHealthcare|Biotechnology|US
$0.91
+0.06 (+6.65%)
Cash / Share
$2.63
Clinical Trials (19)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03328078 CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | P1P2 | Recruiting | 152 | Open-label | Emavusertib, Ibrutinib |
| NCT07271667 A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies | Chronic Lymphocytic Leukemia, B-cell Malignancies | P2 | Recruiting | 108 | Open-label | Emavusertib, Zanubrutinib |
| NCT05187182 CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | Gastric Cancer, Esophageal Cancer | P1 | Recruiting | 42 | Open-label | CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7 |
| NCT07107750 Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | P1 | Recruiting | 48 | Open-label | Emavusertib, Gemcitabine, Cisplatin, Durvalumab |
| NCT00004487 Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients With Vesicoureteral Reflux | Vesicoureteral Reflux | P3 | Unknown | 60 | — | chondrocyte-alginate gel suspension |
| NCT04278768 Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia, Myelodysplastic Syndrome | P1P2 | SUSPENDED | 366 | Open-label | Emavusertib, Venetoclax, Emavusertib |
| NCT02674750 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | P2 | Completed | 70 | RCT, Open-label | CUDC-907 |
| NCT05178342 Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 | Myelodysplastic Syndromes, Anemia | P2 | Terminated | 38 | Open-label | CA-4948 |
| NCT01742988 Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | Lymphoma, Relapsed Lymphoma | P1 | Completed | 106 | Open-label | fimepinostat, Rituximab, venetoclax |
| NCT01908413 Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma | Lymphoma | P1 | Terminated | 23 | Open-label | CUDC-427 |
| NCT01384799 Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer | Head and Neck Cancer | P1 | Completed | 12 | Open-label | CUDC-101, Cisplatin |
| NCT02909777 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | Lymphoma, Neuroblastoma | P1 | Completed | 26 | Open-label | CUDC-907 |
| NCT01171924 A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors | Head and Neck Cancer, Liver Cancer | P1 | Completed | 47 | RCT, Open-label | CUDC-101, CUDC-101 |
| NCT02812875 A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas | Advanced Solid Tumors or Lymphomas | P1 | Completed | 71 | Open-label | CA-170 |
| NCT02307240 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer | P1 | Completed | 43 | Open-label | CUDC-907 |
| NCT04475523 Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies | Solid Tumor | P1 | Completed | 26 | Open-label | CI-8993 |
| NCT00728793 A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors | Tumors | P1 | Completed | 25 | Open-label | CUDC-101 |
| NCT01702285 Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients | Cancer | P1 | Terminated | 3 | Open-label | CUDC-101 |
| NCT03893487 Fimepinostat in Treating Brain Tumors in Children and Young Adults | Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma | Early P1 | Completed | 30 | Open-label | Fimepinostat |